Table 1.
7-Day Point Prevalence Abstinence at Week 6 by Adherence, n (% Down Columns)
| All randomized | Placebo | 150-mg Bupropion SR | 300-mg Bupropion SR | |||||
|---|---|---|---|---|---|---|---|---|
| Highly adherent | Low adherent | Highly adherent | Low adherent | Highly adherent | Low adherent | Highly adherent | Low adherent | |
| CO confirmed | ||||||||
| Abstinent | 120 (65.93 ) | 39 (33.62 ) | 33 (55.00) | 16 (39.02) | 39 (65.00 ) | 13 (34.21 ) | 48 (77.42 ) | 10 (27.03 ) |
| Not abstinent | 62 (34.07 ) | 77 (66.38 ) | 27 (45.00) | 25 (60.98) | 21 (35.00 ) | 25 (65.79 ) | 14 (22.58 ) | 27 (72.97 ) |
| Cotinine confirmed | ||||||||
| Abstinent | 24 (13.48 ) | 5 (4.39 ) | 3 (5.08) | 2 (5.00) | 9 (14.75) | 3 (8.11) | 12 (20.69 ) | 0 (0.00 ) |
| Not abstinent | 154 (86.52 ) | 109 (95.61 ) | 56 (94.92) | 38 (95.00) | 52 (85.25) | 34 (91.89) | 46 (79.31 ) | 37 (100.00 ) |
CO = carbon monoxide; SR = Sustained Release. Bolded results have a statistically significant test or a Fisher’s Exact test.